Stock comparison
Pro Medicus Limited
PME.AX$16.79BHealthcare Market cap, Sector
Tandem Diabetes Care
TNDM$1.3BHealthcare Market cap, Sector
Overall winner
Pro Medicus Limited
PME.AX 70 TNDM
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
PME.AX7wins
0winsTNDM
78B
F24
90A
B73
98A
F30
100A
D45
84B
F0
91A
F27
96A
F22
Side-by-side metrics
| Metric | PME.AX | TNDM |
|---|---|---|
| Market cap | Winner: $16.79B | $1.3B |
| P/E (TTM) | 147.6x | - Winner |
| EV/EBIT | 106.8x | - Winner |
| ROIC (TTM) | Winner: 42.56% | -8.44% |
| Gross margin | Winner: 99.85% | 54.93% |
| Net margin | Winner: 54.12% | -9.2% |
| Revenue CAGR 5y | Winner: 31.61% | 9.62% |
| EPS CAGR 5y | 37.34% | - |
| Debt / Equity | Winner: 0.0x | 5.5x |
| Dividend yield | - | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
PME.AX leads on
- ROIC (TTM)42.56%vs -8.44%+120%
- Net margin54.12%vs -9.2%+117%
- Debt / Equity0.0xvs 5.5x+100%
- Market cap$16.79Bvs $1.3B+92%
TNDM leads on
- EV/EBIT-vs 106.8x+119%
- P/E (TTM)-vs 147.6x+107%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.